Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor

Journal of Cystic Fibrosis

Volumn 15, Issue 1, 2016, Pages 67-73

  Bratcher, Preston E ^a,g   Rowe, Steven M ^a,b,c,e,f   Reeves, Ginger ^b,e   Roberts, Tambra ^b,e   Szul, Tomasz ^a,g   Harris, William T ^b,e,g   Tirouvanziam, Rabindra ^g,h,i   Gaggar, Amit ^a,b,c,d,g  

^a and Clinical Center   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

^e University of Alabama at Birmingham and Children's Hospital   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

Author keywords

Blood; CFTR; G551D; Ivacaftor; Leukocyte; VX 770

Indexed keywords

CD11B ANTIGEN; CD16 ANTIGEN; CD63 ANTIGEN; CHEMOKINE RECEPTOR CXCR2; IVACAFTOR; AMINOPHENOL DERIVATIVE; CFTR PROTEIN, HUMAN; CHLORIDE CHANNEL STIMULATING AGENT; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; QUINOLONE DERIVATIVE;

ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; EX VIVO STUDY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKOCYTE ACTIVATION; MALE; MONOCYTE; NEUTROPHIL; BLOOD; DRUG EFFECTS; GENETICS; IMMUNOLOGY; MUTATION; STATISTICS;

ADULT; AMINOPHENOLS; ANTIGENS, CD11B; ANTIGENS, CD63; CHLORIDE CHANNEL AGONISTS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; HUMANS; MALE; MONOCYTES; MUTATION; NEUTROPHILS; QUINOLONES; STATISTICS AS TOPIC;

EID: 84959557066     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2015.02.010     Document Type: Article

References (27)

1. Collins F.S. Cystic fibrosis: molecular biology and therapeutic implications. Science 1992, 256(5058):774-779.
2. Quinton P.M. Cystic fibrosis: lessons from the sweat gland. Physiology (Bethesda) 2007, 22:212-225.
3. Bradbury N.A., Jilling T., Berta G., Sorscher E.J., Bridges R.J., Kirk K.L. Regulation of plasma membrane recycling by CFTR. Science 1992, 256(5056):530-532.
4. Rowe S.M., Miller S., Sorscher E.J. Cystic fibrosis. N Engl J Med 2005, 352(19):1992-2001.
5. Ratner D., Mueller C. Immune responses in cystic fibrosis: are they intrinsically defective?. Am J Respir Cell Mol Biol 2012, 46(6):715-722.
6. Painter R.G., Marrero L., Lombard G.A., Valentine V.G., Nauseef W.M., Wang G. CFTR-mediated halide transport in phagosomes of human neutrophils. J Leukoc Biol 2010, 87(5):933-942.
7. Rieber N., Hector A., Carevic M., Hartl D. Current concepts of immune dysregulation in cystic fibrosis. Int J Biochem Cell Biol 2014, 52:108-112.
8. Gaggar A., Jackson P.L., Noerager B.D., O'Reilly P.J., McQuaid D.B., Rowe S.M., et al. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol 2008, 180(8):5662-5669.
9. Murphy B.S., Bush H.M., Sundareshan V., Davis C., Hagadone J., Cory T.J., et al. Characterization of macrophage activation states in patients with cystic fibrosis. J Cyst Fibros 2010, 9(5):314-322.
10. Greene C.M., McElvaney N.G. Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery. Br J Pharmacol 2009, 158(4):1048-1058.
11. Kotha K., Clancy J.P. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence. Ther Adv Respir Dis 2013, 7(5):288-296.
12. Accurso F.J., Rowe S.M., Clancy J.P., Boyle M.P., Dunitz J.M., Durie P.R., et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010, 363(21):1991-2003.
13. Ramsey B.W., Davies J., McElvaney N.G., Tullis E., Bell S.C., Drevinek P., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011, 365(18):1663-1672.
14. Symposium session summaries. Pediatric pulmonology. 2013, 48:103-206. S36.
15. Laval J., Touhami J., Herzenberg L.A., Conrad C., Taylor N., Battini J.L., et al. Metabolic adaptation of neutrophils in cystic fibrosis airways involves distinct shifts in nutrient transporter expression. J Immunol 2013, 190(12):6043-6050.
16. Niessen H.W., Verhoeven A.J. Differential up-regulation of specific and azurophilic granule membrane markers in electropermeabilized neutrophils. Cell Signal 1992, 4(5):501-509.
17. Diamond M.S., Springer T.A. A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen. J Cell Biol 1993, 120(2):545-556.
18. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140(6):821-832.
19. Niedel J.E., Kuhn L.J., Vandenbark G.R. Phorbol diester receptor copurifies with protein kinase C. Proc Natl Acad Sci U S A 1983, 80(1):36-40.
20. Rose J.J., Foley J.F., Murphy P.M., Venkatesan S. On the mechanism and significance of ligand-induced internalization of human neutrophil chemokine receptors CXCR1 and CXCR2. J Biol Chem 2004, 279(23):24372-24386.
21. Leino L., Lilius E.M. The up- and down-modulation of immunoglobulin G Fc receptors and complement receptors on activated human neutrophils depends on the nature of activator. J Leukoc Biol 1992, 51(2):157-163.
22. Pohl K., Hayes E., Keenan J., Henry M., Meleady P., Molloy K., et al. A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy. Blood 2014, 124(7):999-1009.
23. Yoshimura K., Nakamura H., Trapnell B.C., Chu C.S., Dalemans W., Pavirani A., et al. Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin. Nucleic Acids Res 1991, 19(19):5417-5423.
24. Del Porto P., Cifani N., Guarnieri S., Di Domenico E.G., Mariggio M.A., Spadaro F., et al. Dysfunctional CFTR alters the bactericidal activity of human macrophages against Pseudomonas aeruginosa. PLoS One 2011, 6(5):e19970.
25. Sorio C., Buffelli M., Angiari C., Ettorre M., Johansson J., Vezzalini M., et al. Defective CFTR expression and function are detectable in blood monocytes: development of a new blood test for cystic fibrosis. PLoS One 2011, 6(7):e22212.
26. Sprague R.S., Ellsworth M.L., Stephenson A.H., Kleinhenz M.E., Lonigro A.J. Deformation-induced ATP release from red blood cells requires CFTR activity. Am J Physiol 1998, 275(5 Pt 2):H1726-H1732.
27. Cohen T.S., Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 2012, 18(4):509-519.